| Literature DB >> 12022983 |
Marko Kornmann1, Karl H Link, Inga Galuba, Kati Ott, Wolfgang Schwabe, Peter Häusler, Peter Scholz, Jörn Sträter, Sucan Polat, Bernhard Leibl, Erika Kettner, Christoph Schlichting, Wolfram Baumann, Harald Schramm, Ute Hecker, Karsten Ridwelski, Jürgen H Vogt, Klaus-Ullrich Zerbian, Frank Schütze, Ernst D Kreuser, Detlev Behnke, Hans G Beger.
Abstract
Patients with International Union Against Cancer (UICC) stage IIb and III colon cancer and stage II and III rectal cancer may receive adjuvant chemotherapy with 5-fluorouracil (5-FU). High levels of thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) have been associated with resistance to 5-FU in advanced colorectal cancer. The aim of this study was to investigate the association of TS and DPD mRNA levels with recurrence-free survival in patients with colorectal cancer who are receiving adjuvant 5-FU-based chemotherapy. TS and DPD mRNA quantitation was retrospectively performed in primary colorectal cancer specimens from patients receiving adjuvant 5-FU using a reverse transcription- polymerase chain reaction technique. The median TS mRNA level in patients with a recurrence (n = 142) was 0.68, and in patients without a recurrence (n = 206) the median level was 0.80 (P < 0.01). Patients with a recurrence who had a low TS level (TS < or = 0.9; n = 102) had a median recurrence-free survival of 18 months (range 3.0 to 54 months), and those with a high TS level (TS > 0.9; n = 40) had a median recurrence-free survival of 11 months (range 1.7 to 53 months; P = 0.0024). There was no difference in the median recurrence-free survival of patients with low and high DPD mRNA levels. The TS mRNA level may be a useful marker to predict the time to recurrence in patients with colorectal cancer who are receiving adjuvant 5-FU treatment.Entities:
Mesh：
Substances：
Year: 2002 PMID： 12022983 DOI： 10.1016/s1091-255x(02)00018-5
Source DB: PubMed Journal: J Gastrointest Surg ISSN： 1091-255X Impact factor: 3.452